Laplace Interventional
Plymouth, US · Founded 2020 · 2 known investors
Laplace Interventional develops a transcatheter tricuspid valve replacement system that delivers a prosthetic valve percutaneously, avoiding open-heart surgery for patients with tricuspid regurgitation. The company is a medical device developer based in the United States.
HealthtechMedical Devices
Founders & leadership
RI
Ramji IyerExecutive Officer, Director
JH
Jenny H. BarbaDirector
TM
Todd MortierDirector
CM
Colin MorrisonDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$21.2MraisedFeb 2025 · 6 investors · Other Health CareRule 506(b)
▶$21.2MraisedFeb 2025 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jenny H. BarbaDirector
- Todd MortierDirector
- Colin MorrisonDirector
- Ramji IyerExecutive Officer, Director
- Offering amount
- $25M
- Amount sold
- $21.2M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$12.9MraisedJul 2023 · 9 investors · Other Health CareRule 506(b)
▶$12.9MraisedJul 2023 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jenny BarbaDirector
- Ramji IyerExecutive Officer, Director
- Todd MortierDirector
- William DaiDirector
- Offering amount
- $12.9M
- Amount sold
- $12.9M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.9MraisedSep 2021 · 8 investors · Other Health CareRule 506(b)
▶$7.9MraisedSep 2021 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ramji IyerExecutive Officer, Director
- Offering amount
- $7.9M
- Amount sold
- $7.9M
- Minimum investment
- $25K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.